NextCure, Inc. (NXTC) stock
NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.40+0.17 (+2.73%)
Close on Nov 13, 2026Market cap $29.30MP/E –Yield 0.00%
NextCure r&d expenses
Research and development expenses are spending on new products and technology.
NextCure's R&D Expenses for the twelve months ending Jun 30, 2026 was $27.20M, down 45.2% year over year. For fiscal 2025 it was $44.92M, up 8.3% from the year before. The highest annual figure on record is $54.20M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.92M | +8.3% |
| FY2024 | Dec 31, 2024 | $41.49M | -13.4% |
| FY2023 | Dec 31, 2023 | $47.93M | -11.6% |
| FY2022 | Dec 31, 2022 | $54.20M | +8.0% |
| FY2021 | Dec 31, 2021 | $50.19M | +7.8% |
| FY2020 | Dec 31, 2020 | $46.55M | +36.1% |
| FY2019 | Dec 31, 2019 | $34.22M | +72.9% |
| FY2018 | Dec 31, 2018 | $19.79M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.43M | -69.2% |
| Q1 FY2026 | Mar 31, 2026 | $6.83M | -13.4% |
| Q4 FY2025 | Dec 31, 2025 | $6.80M | -23.6% |
| Q3 FY2025 | Sep 30, 2025 | $6.14M | -30.0% |
| Q2 FY2025 | Jun 30, 2025 | $24.09M | +94.0% |
| Q1 FY2025 | Mar 31, 2025 | $7.90M | -30.7% |
| Q4 FY2024 | Dec 31, 2024 | $8.90M | -24.7% |
| Q3 FY2024 | Sep 30, 2024 | $8.77M | -20.3% |
| Q2 FY2024 | Jun 30, 2024 | $12.42M | -7.7% |
| Q1 FY2024 | Mar 31, 2024 | $11.40M | -2.1% |
| Q4 FY2023 | Dec 31, 2023 | $11.83M | -7.8% |
| Q3 FY2023 | Sep 30, 2023 | $11.01M | -18.6% |
| Q2 FY2023 | Jun 30, 2023 | $13.45M | +4.8% |
| Q1 FY2023 | Mar 31, 2023 | $11.65M | -22.5% |
| Q4 FY2022 | Dec 31, 2022 | $12.82M | +4.5% |
| Q3 FY2022 | Sep 30, 2022 | $13.53M | -0.5% |
| Q2 FY2022 | Jun 30, 2022 | $12.83M | +7.4% |
| Q1 FY2022 | Mar 31, 2022 | $15.02M | +21.3% |
| Q4 FY2021 | Dec 31, 2021 | $12.26M | +1.3% |
| Q3 FY2021 | Sep 30, 2021 | $13.60M | +6.7% |
| Q2 FY2021 | Jun 30, 2021 | $11.95M | +7.3% |
| Q1 FY2021 | Mar 31, 2021 | $12.39M | +17.1% |
| Q4 FY2020 | Dec 31, 2020 | $12.11M | +6.2% |
| Q3 FY2020 | Sep 30, 2020 | $12.74M | +47.1% |
| Q2 FY2020 | Jun 30, 2020 | $11.13M | +45.6% |
| Q1 FY2020 | Mar 31, 2020 | $10.58M | +62.4% |
| Q4 FY2019 | Dec 31, 2019 | $11.40M | +82.4% |
| Q3 FY2019 | Sep 30, 2019 | $8.66M | +77.0% |
| Q2 FY2019 | Jun 30, 2019 | $7.64M | +72.4% |
| Q1 FY2019 | Mar 31, 2019 | $6.51M | +54.7% |
| Q4 FY2018 | Dec 31, 2018 | $6.25M | – |
| Q3 FY2018 | Sep 30, 2018 | $4.90M | – |
| Q2 FY2018 | Jun 30, 2018 | $4.43M | – |
| Q1 FY2018 | Mar 31, 2018 | $4.21M | – |
See a number that looks wrong?